[
    {
        "id": 0,
        "title": "Identify People for Screening",
        "x": 0,
        "y": 34,
        "description": "<span style='color:blue'><i><b>Select an option to see more details:</b></i></span><br/><br/><button class='btn btn-primary' data-bs-toggle='collapse' href='#collapseExample1' role='button' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i><b>&nbsp;Types of Screening</b>&nbsp;&nbsp;&nbsp;</button><div class='collapse' id='collapseExample1'><br/><div class='card card-body'><h3><img src='https://i.imgur.com/SFHm3t2.png'>&nbsp;Systematic Strategy</h3><h5>For the screening of DM and atherosclerosis risk factors, a systematic strategy should be used to identify people who are likely to be at high risk.</h5><br/><br/><h3><img src='https://i.imgur.com/tsT2qjP.png'>&nbsp;Opportunistic Assessment</h3><h5>Opportunistic assessment can also be used to identify ASCVD risk in the population but should not be the main strategy.</div></div></h5><br/><br/><button class='btn btn-primary' type='button' data-bs-toggle='collapse' data-bs-target='#collapseExample2' aria-expanded='false aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i><b>&nbsp;Who to Screen?</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample2'><div class='card card-body'><h5>Screen the following people for prediabetes, T2DM and related ASCVD risk factors:<ul><li>Everyone over the age of 40 years.</li><li>Everyone ≥ 30 years of age with a BMI of ≥23.</li><li>All women with a history of either GDM or PCOS.</li><li>All people with a BMI ≥27 kg/m2.</li><li>Screen all adults with two or more of the following risk factors.</li></ul></div><br/><br/></h5></div><button class='btn btn-primary' type='button' data-bs-toggle='collapse' data-bs-target='#collapseExample3' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i><b>&nbsp;Risk Factors</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample3'><div class='card card-body'><h5><img src='https://i.imgur.com/pNs7lrv.png'>&nbsp;BMI ≥23 to <27 kg/m2.</h5><h5><img src='https://i.imgur.com/fK0g3wR.png'>&nbsp;First-degree relative with DM.</h5><h5><img src='https://i.imgur.com/MA182Fe.png'>&nbsp;First-degree relative with CVD at young age (<55 years for a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;male relative and <65 year for a female relative).</h5><h5><img src='https://i.imgur.com/d5v2256.png'>&nbsp;High-risk race/ethnicity.</h5><h5><img src='https://i.imgur.com/dGjw6bF.png'>&nbsp;History of CVD.</h5><h5><img src='https://i.imgur.com/nFqPRxC.png'>&nbsp;Hypertension (BP ≥140/90 mmHg or on therapy for &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;hypertension).</h5><h5><img src='https://i.imgur.com/nBvE3Es.png'>&nbsp;Dyslipidaemia: HDL cholesterol level <0.90 mmol/L (35 mg/dL), a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;triglyceride level >2.82 mmol/L (250 mg/dL), LDL cholesterol level <br/><br/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;> 3.11 mmol/L (120 mg/dL), total cholesterol level >6.18 mmol/L <br/><br/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(240 mg/dL), and/or non-HDL cholesterol > 3.63 mmol/L (150 <br/><br/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;mg/dL); or the patient is on a lipid lowering medication.</h5><h5><img src='https://i.imgur.com/MSADJ3B.png'>&nbsp;Physical inactivity.</h5><h5><img src='https://i.imgur.com/gKEVOG9.png'>&nbsp;Tobacco use.</h5><h5><img src='https://i.imgur.com/faQrQRO.png'>&nbsp;Other clinical conditions associated with insulin resistance.</h5></div></div>",
        "colour": "#932b8f",
        "label": {
            "x": 35000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 1,
        "title": "ASCVD and DM Risk Factors",
        "x": 0,
        "y": 32,
        "description": "<h3>Non-Modifiable Risk Factors</h3><table class='table'><thead><tr class='bg-primary'><th scope='col'>Non-Modifiable Risk Factor</th><th scope='col'>ASCVD Risk Factor</th><th scope='col'>T2DM Risk Factor</th></tr></thead><tbody><tr class='table-primary'><th scope='row'>Age</th><td>Age > 40 years</td><td>Age ≥40 years</td></tr><tr class='bg-light'><th scope='row'>Gender</th><td>Men have a higher prevalence of coronary artery disease until the age of 75 years.</td><td>Women with a previous history of GDM or previous delivery of a baby weighing ≥4 kg (9 lb) are at higher risk of diabetes</td></tr><tr class='table-primary'><th scope='row'>Family history</th><td>Family history of premature ASCVD.</td><td>Family history of T2DM.</td></tr><tr class='bg-light'><th scope='row'>Ethnicity</th><td colspan='2'>Member of an at-risk racial or ethnic subgroup e.g. South Asian.</td></tr></tbody></table><br/><h3>Modifiable Risk Factors</h3><table class='table'><thead><tr class='bg-primary'><th scope='col'>Modifiable Risk Factor</th><th scope='col'>ASCVD Risk Factor</th><th scope='col'>T2DM Risk Factor</th></tr></thead><tbody><tr class='table-primary'><th scope='row'>Metabolic syndrome</th><td>Age >Yes</td><td>Yes</td></tr><tr class='table-light'><th scope='row'>Impaired glucose metabolism</th><td>Yes</td><td>Yes</td></tr><tr class='table-primary'><th scope='row'>Diabetes mellitus</th><td>Yes</td><td>Diagnosed</td></tr><tr class='bg-light'><th scope='row'>Hypertension</th><td>Yes</td><td>Yes</td></tr><tr class='table-primary'><th scope='row'>Dyslipidaemia</th><td>Yes</td><td>Yes</td></tr><tr class='bg-light'><th scope='row'>Tobacco use</th><td>Yes</td><td>Yes</td></tr><tr class='table-primary'><th scope='row'>Sedentary lifestyle</th><td>Yes</td><td>Yes</td></tr><tr class='bg-light'><th scope='row'>Unhealthy diet</th><td>Yes</td><td>Yes</td></tr><tr class='table-primary'><th scope='row'>Psychosocial stress</th><td>Yes</td><td>Yes</td></tr><tr class='bg-light'><th scope='row'>Overweight</th><td>Yes</td><td>Yes</td></tr></tbody></table>",
        "colour": "#932b8f",
        "label": {
            "x": -15000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 2,
        "title": "Depression & Anxiety \nScreening & Assessment",
        "x": 2,
        "y": 32,
        "description": "<span style='color:blue'><i><b>Select an option to see more details:</b></i></span><br/><br/><button class='btn btn-primary' data-bs-toggle='collapse' href='#collapseExample1' role='button' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;<b>Who to Screen?</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample1'><div class='card card-body'><h5>Screening for undiagnosed depression and anxiety should be performed in all adults, including pregnant and postpartum women, who are to be screened for ASCVD or DM.</h5></div><br/></div><button class='btn btn-primary' type='button' data-bs-toggle='collapse' data-bs-target='#collapseExample2' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;<b>How to Screen?</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample2'><div class='card card-body'><h5>Use the PHQ-2 and GAD-2 questions for initial screening for depression and anxiety. If a patient answers positively to the PHQ-2 and/or GAD-2 questions, they should be assessed using the PHQ-9 and/ or GAD-7 questions, respectively, and be seen by a physician.</h5></div><br/></div><button class='btn btn-primary' type='button' data-bs-toggle='collapse' data-bs-target='#collapseExample3' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;<b>Additional Assessments</b>&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample3'><div class='card card-body'><h5>All positive screening results should lead to additional assessment that considers:</h5><h5><img src='https://i.imgur.com/HsHMZUe.png'>&nbsp;The severity of depression and anxiety.</h5><h5><img src='https://i.imgur.com/nOe6CZb.png'>&nbsp;First-degree relative with DM.</h5><h5><img src='https://i.imgur.com/dHayUo6.png'>&nbsp;Comorbid psychological problems (e.g., anxiety, panic attacks, or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;substance abuse).</h5><h5><img src='https://i.imgur.com/k37oWim.png'>&nbsp;Other medical conditions.</h5></div></div>",
        "colour": "#932b8f",
        "label": {
            "x": 45000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 3,
        "title": "Measure BMI",
        "x": -15,
        "y": 28,
        "description": "<span style='color:blue'><i><b>Select an option to see more details:</b></i></span><br/><br/><button class='btn btn-primary' data-bs-toggle='collapse' href='#collapseExample1' role='button' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;<b>BMI Calculation</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample1'><div class='card card-body'><h5>Calculate the BMI by measuring weight in kilograms and height in metres.</h5><img src='https://i.imgur.com/QqL2tsU.png' width='100%'><p class='carousel-caption' style='top:35%;width:80%;left:10%'>BMI should be interpreted with caution because the calculation alone it is not a direct measure of adiposity, especially in highly muscular adults. Do not use bio-impedance as a substitute for BMI as evidence to support its use is lacking at present.<br/><br/></p></div><br/></div><button class='btn btn-primary' type='button' data-bs-toggle='collapse' data-bs-target='#collapseExample2' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;<b>Obesity</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample2'><div class='card card-body'><h5>Obesity is commonly defined by a measurement of BMI of ≥30 kg/m2 in Western populations, however different ethnic-specific cut points for defining obesity may need to be considered. Emerging evidence points towards lower BMI levels being associated with greater risk for metabolic diseases based on ethnicity.</h5><br/><h4>The degree of overweight and obesity can be classified:</h4><table class='table'><thead><tr class='bg-primary'><th scope='col'>BMI</th><th scope='col'>Obesity Class</th></tr></thead><tbody><tr class='table-primary'><td>BMI 25.00 - 29.99 kg/m2</td><td>Overweight</td></tr><tr class='bg-light'><td>BMI 30.00 - 34.99 kg/m2</td><td>Obesity Class I</td></tr><tr class='table-primary'><td>BMI 35.00 - 39.99 kg/m2</td><td>Obesity Class II</td></tr><tr class='bg-light'><td>BMI ≥40.00 kg/m2</td><td>Obesity Class III (extreme obesity)</td></tr></tbody></table></div><br/></div><button class='btn btn-primary' type='button' data-bs-toggle='collapse' data-bs-target='#collapseExample3' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;<b>Risks Associated with BMI</b></button><br/><br/><div class='collapse' id='collapseExample3'><div class='card card-body'><h5><img src='https://i.imgur.com/rSRy3xm.png'>&nbsp;Adults are identified at increased risk for CVD at: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<ul><li>BMI 25.00 - 29.99 kg/m2 – Overweight</li><li>BMI ≥30 kg/m2 – Obesity</li></ul></h5><h5><img src='https://i.imgur.com/JWk0D74.png'>&nbsp;Adults are identified at increased risk for of death from all causes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;at BMI ≥30 kg/m2 (Obesity).</h5></div></div>",
        "colour": "#932b8f",
        "label": {
            "x": -6000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 4,
        "title": "Measure Waist Circumference",
        "x": -5,
        "y": 28,
        "description": "<span style='color:blue'><i><b>Select an option to see more details:</b></i></span><br/><br/><button class='btn btn-primary' data-bs-toggle='collapse' href='#collapseExample1' role='button' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;<b>Process</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample1'><div class='card card-body'><h5>Follow the WHO STEPS protocol for measuring waist circumference:<br/>Measure waist circumference, locate the upper hip bone and the top of the right iliac crest. Place a measuring tape in a horizontal plane around the abdomen at the level of the iliac crest. Before reading the tape measure, ensure that the tape is snug, but does not compress the skin, and is parallel to the floor. The measurement is made at the end of a normal expiration.</h5></div><br/></div><button class='btn btn-primary' type='button' data-bs-toggle='collapse' data-bs-target='#collapseExample2' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;<b>Who to measure?</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample2'><div class='card card-body'><h5>Consider measuring waist circumference in people with a BMI ≤35 kg/m2.</h5></div><br/></div><button class='btn btn-primary' type='button' data-bs-toggle='collapse' data-bs-target='#collapseExample3' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;<b>Waist Circumference Threshold</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample3'><div class='card card-body'><h5>For screening and risk assessment purposes in people of Middle Eastern ethnicity, use a waist circumference threshold of ≥90 cm (35 inches) in men and ≥80 cm (31.5 inches) in women for diagnosing central adiposity. However, thresholds for acceptable waist circumferences vary between ethnic groups. The table below outlines the upper limits of acceptable waist circumferences in different ethnic groups.</h5><br/><table class='table'><thead><tr class='bg-primary'><th scope='col'>Ethnic Group</th><th scope='col'>Waist Circumference Thresholds</th><th></th></tr></thead><tbody><tr  class='table-primary'><th scope='row'>European</th><td>Men<br/>Women</td><td>≥ 94 cm (37 inches)≥ 80 cm (31.5 inches)</td></tr><tr  class='bg-light'><th scope='row'>South Asian, Chinese or Japanese</th><td>Men<br/>Women</td><td>≥ 90 cm (35 inches) ≥ 80 cm (31.5 inches)</td></tr><tr  class='table-primary'><th scope='row'>Middle Eastern</th><td colspan='2'>Use South Asian recommendations until more specific data are available [R-GDG].</td></tr><tr  class='bg-light'><th scope='row'>Ethnic south and central American</th><td colspan='2'>Use South Asian recommendations until more specific data are available</td></tr><tr  class='table-primary'><th scope='row'>Sub-Saharan African</th><td colspan='2'>Use European data until more specific data are available</td></tbody></table></div><br/></div><button class='btn btn-primary' type='button' data-bs-toggle='collapse' data-bs-target='#collapseExample4' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;<b>Risks Associated with Waist Circumference</b></button><br/><br/><div class='collapse' id='collapseExample4'><div class='card card-body'><h5>Waist circumference along with BMI can be used as a measure to assess risk; however, if the BMI is >35 kg/m2, the waist circumference does not add to the absolute measure of risk. A larger waist circumference is a recognised risk factor of developing atherosclerosis and DM in an individual.</h5></div></div>",
        "colour": "#932b8f",
        "label": {
            "x": -13000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 5,
        "title": "Measure Neck Circumference",
        "x": 5,
        "y": 28,
        "description":"Neck circumference (NC) is considered a simple and accurate way of assessing overweight and obesity in adults.<br/><br/><p><button class='btn btn-primary' data-bs-toggle='collapse' href='#collapseExample1' role='button' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;Process&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><div class='collapse' id='collapseExample1'><div class='card card-body'><h5>NC should be measured with the individual standing erect with their head positioned in the horizontal plane. The superior border of a tape measure should be placed just below the laryngeal prominence and applied perpendicular to the long axis of the neck.</h5></div><br/></div><button class='btn btn-primary' type='button' data-bs-toggle='collapse' data-bs-target='#collapseExample2' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i>&nbsp;Neck Circumference Threshold&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample2'><div class='card card-body'><h5>NC above ≥40 cm in Caucasian men and ≥34cm in Caucasian women are associated with increased cardio-metabolic risk. Precise cut-offs in the Qatari population remain to be determined.</h5></div></div>",
        "colour": "#932b8f",
        "label": {
            "x": -13000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 6,
        "title": "Measure Blood Pressure",
        "x": 15,
        "y": 28,
        "description":"<h5>Correct measurement of blood pressure (BP) is essential for accurate determination of ASCVD risk.</h5><br/><h4><br/>Steps for Blood Measurement</h4><br/><h4><img src='https://i.imgur.com/b0WLtTd.png'>&nbsp;<b>Patient's Preparation</h4></b><h5>Ensure the patient:<ul><li>Relaxes for more than 5 minutes, sitting in a chair with their feet on the floor and back supported.</li><li>Avoids caffeine, exercise, and smoking for at least 30 min before BP is measured.</li><li>Has an empty bladder.</li><li>Does not talk during the rest time or during BP measurement:</li><li>Removes all clothing covering the area where the cuff will be placed.</li></ul></h5><img src='https://i.imgur.com/QqL2tsU.png' width='100%'><p class='carousel-caption' style='top:16%;width:80%;left:10%'>BP measured while the patient is sitting or lying on an examining table does not fulfil these criteria</p><h4><img src='https://i.imgur.com/io6lhZ0.png'>&nbsp;<b>Technique for BP Measurement</b></h4><h5>Use correct technique for BP measurement:<ul><li>The BP device should have been validated and should be calibrated periodically.</li><li>The person’s arm should be supported (e.g. resting on a desk).</li><li>The middle of the cuff should be placed on the patient’s upper arm at the level of the right atrium (the midpoint of the sternum).</li><li>The correct cuff size should be used, ensuring the bladder encircles 80% of the arm.</li><li>he diaphragm or bell of the stethoscope can be used for auscultatory readings.</li><li>Palpate the radial or brachial pulse to check for pulse irregularity.</li></ul><h5><br/><img src='https://i.imgur.com/QqL2tsU.png' width='100%'><p class='carousel-caption' style='top:32%;width:80%;left:10%'><b>If the pulse is irregular:</b><br/><br/><span align='left'>Do not use automated devices.<br/><br/>Measure BP manually using direct auscultation over the brachial artery.</span></p></h5><br/><br/>BP cuff size selection in adults showing arm circumference to cuff size.<ul><li>22 to 26 cm for a small adult.</li><li>27 to 34 cm for an <span style='color:red;'>average</span> adult.</li><li>35 to 44 cm for a large adult.</li><li>45 to 52 cm for an adult thigh</li></ul><br/><h4><img src='https://i.imgur.com/OgOUeSQ.png'>&nbsp;<b>Measurement Take</b></h4><br/><h5>Take the correct measurements for diagnosis of elevated BP/hypertension:<ul><li>At the first visit, the BP should be recorded in both arms.</li><li>The arm that gives the higher BP reading should be used for any further readings.</li><li>Consistent inter‐arm differences of over 20/10 mmHg may suggest pathology warranting specialist referral.</li></ul><br/></h5><h5><img src='https://i.imgur.com/QqL2tsU.png' width='100%'><p class='carousel-caption' style='top:56%;width:80%;left:10%'>Repeat BP measurements should be done 15 minutes apart, if abnormal.</p></h5><h4><b>How to Measure BP When Using an Auscultatory Method</b></h4><br/>Palpate the radial pulse for obliteration to estimate the systolic blood pressure (SBP).</li><li>The cuff should be inflated 20 to 30 mmHg above the pulse obliteration level to assess the BP level by auscultation.</li><li>The cuff pressure should be deflated by 2 mmHg per second while listening for Korotkoff sounds.</li></ul></h5><br/><h4><img src='https://i.imgur.com/Cno3zxD.png'><b>&nbsp;BP Readings Documentation</b></h4><br/><h5>Document accurate BP readings correctly.<ul><li>Note the SBP and diastolic blood pressure (DBP).</li><li>Document what time the most recent BP medication was taken before the BP was measured.</li><li>Use an average of ≥2 readings to estimate the BP level, if abnormal.</li><br/></h5><img src='https://i.imgur.com/QqL2tsU.png' width='100%'><p class='carousel-caption' style='top:78%;width:80%;left:10%'>If using the auscultatory method record:<br/><br/>SBP at onset of the first Korotkoff sound<br/>DBP at disappearance of all Korotkoff sounds<br/>Use the nearest even number.</p><br/><br/><h4><img src='https://i.imgur.com/nAQLjT0.png'><b>&nbsp;</b>BP Classification</h4><br/><h5>For high blood pressure prevention and treatment, BP should be categorized as detailed in the table below. If readings for a patient fall into two categories, the higher category should be selected.</h5><table class='table'><thead><tr class='bg-primary'><th scope='col'>BP Category</th><th scope='col'>SBP</th><th scope='col'>And/Or</th><th>DBP</th></tr></thead><tbody><tr class='table-primary'><td>Normal BP</td><td>< 120 mmHgM</td><td>And</td><td>< 80 mmHg</td></tr><tr class='bg-light'><td>Elevated BP</td><td>120-129 mmHg</td><td>And</td><td>< 80 mmHg</td></tr><tr class='table-primary'><td>Hypertension Stage 1</td><td>130-139 mmHg</td><td>Or</td><td>80-89 mmHg</td></tr><tr class='bg-light'><td>Hypertension Stage 2</td><td>≥ 140 mmHg</td><td>Or</td><td>≥ 90 mmHg</td></tr></tbody></table>",
        "colour": "#932b8f",
        "label": {
            "x": -10000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },   
    {
        "id": 7,
        "title": "Blood Tests",
        "x": 0,
        "y": 24,
        "description":"<h4>Undertake the following screening blood tests:</h4><h5><img src='https://i.imgur.com/Hq7Unzq.png'>&nbsp;Glycated haemoglobin (HBA1c).</h5><h5><img src='https://i.imgur.com/l12Qv9o.png'>&nbsp;Fasting glucose (if possible).</h5><h5><img src='https://i.imgur.com/1SBWzkS.png'>&nbsp;Fasting or non-fasted, lipids.</h5><br/><h4>&nbsp;When using HBA1c, it should be noted that:</h4><h5><img src='https://i.imgur.com/5KvEK0Y.png'>&nbsp;Using HBA1c to screen for prediabetes may be problematic in adults &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with certain haemoglobinopathies or conditions that affect red blood<br/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cell turnover.</h5><h5><img src='https://i.imgur.com/45nLK4w.png'>&nbsp;Testing should be performed in a laboratory using a method that is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NGSP-certified and standardised to the DCCT assay.</h5>",
        "colour": "#932b8f",
        "label": {
            "x": -5000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },  
    {
        "id": 8,
        "title": "ASCVD Risk Calculation",
        "x": 0,
        "y": 22,
        "description":"<h3>ASCVD risk calculation tool</h3><p><h5>The <a href='https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/' target='_blank'>ACC/AHA Pooled Cohort Equations</a> should be used to estimate 10-year ASCVD risk in appropriate individuals with or without diabetes.<p/>The tool can only provide an approximate value of ASCVD risk − interpretation of risk scores should always reflect informed clinical judgement.<br/><br/><p><button class='btn btn-primary' data-bs-toggle='collapse' href='#collapseExample1' role='button' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i><b>&nbsp;Should be used</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button><div class='collapse' id='collapseExample1'><div class='card card-body'>The App should be used for primary prevention patients (those without ASCVD) only.<br/><br/></div></div><button class='btn btn-primary' type='button' data-bs-toggle='collapse' data-bs-target='#collapseExample2' aria-expanded='false' aria-controls='collapseExample'><i id='arrow' class='fa fa-angle-right'></i><b>&nbsp;Should not be used</b>&nbsp;&nbsp;&nbsp;&nbsp;</button><br/><br/><div class='collapse' id='collapseExample2'><div class='card card-body'>Risk estimation tools should not be used for the following groups of patients:<br/><ul><li>People aged over 75 years</li><li>Patients with a primary dyslipidemia.</li><li>Patients with established CVD.</li><li>Patients with T1DM ASCVD risk assessment should be based on the individual’s age and the duration since diagnosis.</li><li>Patients with Chronic kidney disease (CKD) stages 3-5.</li></ul></div></div><br/></h5><h3>Risk Stratification</h3><br/><h5>Patients without established clinical ASCVD who are at increased risk of ASCVD include:</h5><h4><img src='https://i.imgur.com/hRMDWvX.png'>&nbsp;Patients with risk score of ≥5% over 10 years - &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;calculated using the ACC/AHA Pooled Cohort &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equations; or</h4><br/><h4><img src='https://i.imgur.com/Jx5472Q.png'>&nbsp;Any of the following groups:</h4><h5><ul><li>People aged over 75 years.</li><li>Patients with a primary dyslipidemia.</li><li>Patients with established CVD.</li><li>Patients with T1DM. ASCVD risk assessment should be based on the patient’s age and the duration since diagnosis.</li><li>Patients with CKD stages 3-5.</li><li>Patients with an LDL cholesterol of ≥4.9 mmol/L.</li></ul><br/><h4><img src='https://i.imgur.com/Ytk4WJZ.png'>&nbsp;People at low risk of ASCVD include those aged <75 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;years without clinical ASCVD; and with a calculated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ASCVD risk score of <5% over 10 years.</h4><br/><h3>Communication of risk assessment </h3><h5>When communicating to the screened individual about their risk assessment and treatment, offer information on their risk of ASCVD, the benefits and harms of either intervention or failure to intervene.<br/>Forms to offer information</h5><br/><h4><img src='https://i.imgur.com/PEvl0VJ.png'>&nbsp;Individualised risk and benefit scenarios.</h4><h4><img src='https://i.imgur.com/yl1EFST.png'>&nbsp;Risk of events numerically.</h4><h4><img src='https://i.imgur.com/p4QIiyB.png'>&nbsp;Diagrams and text.</h4>",
        "colour": "#932b8f",
        "label": {
            "x": -12000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 9,
        "title": "Diagnosis of T2DM",
        "x": -15,
        "y": 14,
        "description":"<h5>T2DM is diagnosed if any of the following criteria are met:</h5><h4><img src='https://i.imgur.com/j9jhjqT.png'>&nbsp;HBA1C of ≥6.5%.</h4><h4><img src='https://i.imgur.com/30zCwjL.png'>&nbsp;Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL).</h4><h4><img src='https://i.imgur.com/JdIrpp5.png'>&nbsp;2-hour plasma glucose of ≥11.1 mmol/L (200 mg/dL) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;during an oral glucose tolerance test (OGTT) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;performed using a glucose load containing the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;equivalent of 75g of anhydrous glucose dissolved in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;water.</h5><br/><img src='https://i.imgur.com/QqL2tsU.png' width='100%'><p class='carousel-caption' style='top:67%;width:80%;left:10%'>It is recommended that single tests, such as HBA1C and fasting glucose, be repeated for confirmation.</p>",
        "colour": "#f27aaa",
        "label": {
            "x": -9000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 10,
        "title": "Management of T2DM",
        "x": -15,
        "y": 10,
        "description":"<h5>Type 2 Diabetes mellitus:</h5><h4><img src='https://i.imgur.com/H23liCb.png'>&nbsp;Should be managed predominantly in a primary care &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;setting.</h4><h4><img src='https://i.imgur.com/G4bYoZj.png'>&nbsp;Complex cases should be referred to secondary &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;care.</h4><br/><h5>Refer to the <a href='https://www.moph.gov.qa/english/OurServices/eservices/Pages/Clinical-Guidelines.aspx#D' target='_blank'>MOPH National Clinical Guidelines</a> on Diabetes for detailed information on management.</h5>",
        "colour": "#ee2b2f",
        "label": {
            "x": -10000,
            "y": 8000
        },
        "type": "M7342 10267 l-2652 -2652 2655 -2655 2655 -2655 2655 2655 2655 2655 -2652 2652 c-1459 1459 -2655 2653 -2658 2653 -3 0 -1199 -1194 -2658 -2653z"
    },
    {
        "id": 11,
        "title": "Diagnosis of Prediabetes",
        "x": -5,
        "y": 14,
        "description":"<h5>Prediabetes is diagnosed if any of the following criteria are met:<br/><ul><li>HBA1C of 5.7% - 6.4%</li><li>Fasting plasma glucose 5.6 - 6.9 mmol/L (100 - 125 mg/dL).</li><li>2-hour plasma glucose 7.8 - 11.0 mmol/L (140 - 199 mg/dL) during OGTT performed using a glucose load containing the equivalent of 75g of anhydrous glucose dissolved in water.</li></ul></h5><br/><img src='https://i.imgur.com/QqL2tsU.png' width='100%'><p class='carousel-caption' style='top:55%;width:80%;left:10%'>It is recommended that single tests, such as HBA1C and fasting glucose, be repeated for confirmation.</p>",
        "colour": "#f27aaa",
        "label": {
            "x": -12000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 12,
        "title": "Management of Prediabetes",
        "x": -5,
        "y": 10,
        "description":"<h3><b>Healthy lifestyle intervention</b></h3><br/><h5>Those with prediabetes should:</h5><h5><img src='https://i.imgur.com/Obj0Hzi.png'>&nbsp;Be referred to an intensive behavioural lifestyle intervention &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;programme (e.g. Wellness Centers or health educators in primary &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;care).</h5><h5><img src='https://i.imgur.com/cHLZKWl.png'>&nbsp;Achieve weight loss</h5><h5><img src='https://i.imgur.com/J8b63Vl.png'>&nbsp;Increase physical activity.</h5><h5><img src='https://i.imgur.com/2zuHu9D.png'>&nbsp;Use Technology-assisted tools</h5><h5><img src='https://i.imgur.com/ktXSpcN.png'>&nbsp;Participate in Diabetes self-management education (DSME) and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;support (DSMS) programmes</h5><h5><img src='https://i.imgur.com/cDoxYnJ.png'>&nbsp;Participate in traditional face-to-face and coach-driven programmes.</h5><br/><h3><b>Nutrition & Weight management</b></h3><br/><h5>Refer all adults at high risk for T2DM and those diagnosed with prediabetes to a dietitian for individualised medical nutrition therapy.</h5><img src='https://i.imgur.com/QqL2tsU.png' width='100%'><p class='carousel-caption' style='top:35%;width:80%;left:10%'>Refer to the <a href='https://www.moph.gov.qa/english/OurServices/eservices/Pages/Clinical-Guidelines.aspx#O' target='_blank'>MOPH National Clinical Guideline</a> on Obesity for detailed information on management of the condition.</p><br/><h3><b>Physical activity</b></h3><h5>In adults with prediabetes suggest 150 minutes per week of moderate intensity physical activity e.g., brisk walking.</h5><br/><h3><b>Medication</b></h3><h5>Metformin treatment in prediabetes for prevention of T2DM has the strongest evidence base and long-term safety profile.</h5><br/><span style='color:red;'><h3><b>Who should be medicated?</b></h3></span><h5>Should be considered in everyone with prediabetes (if there are no contraindications), and especially in the following groups:<ul><li>People with a BMI ≥ 27 kg/m2.</li><li>People aged < 60 years.</li><li>Women with prior gestational diabetes mellitus.</li></ul><br/><span style='color:red;'><h3><b>Dosage</b></h3></span><h5>Metformin dose should be slowly titrated upwards up to a dose of 1,000 mg twice a day or maximum tolerated dose.</h5><img src='https://i.imgur.com/QqL2tsU.png' width='100%'><p class='carousel-caption' style='top:73%;width:80%;left:10%'>People with prediabetes should be screened and treated for other modifiable risk factors of ASCVD.</p><br/><h3><b>Monitoring</b></h3><h5>At least annual monitoring should be performed to check for the development of diabetes. This should include:<ul><li>HBA1C.</li><li>Fasting and postprandial glucose.</li></ul></h5><img src='https://i.imgur.com/QqL2tsU.png' width='100%'><p class='carousel-caption' style='top:91%;width:80%;left:10%'>In patients on metformin, annual measurement of vitamin B12 levels should be carried out.</p>",
        "colour": "#ee2b2f",
        "label": {
            "x": -14000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 13,
        "title": "No Diagnosis \n of DM or Prediabetes",
        "x": 5,
        "y": 14,
        "description":"<h5>When there is no diagnosis of Diabetes Mellitus (DM) or prediabetes, diabetes risk calculation should be the next step.</h5>",
        "colour": "#f27aaa",
        "label": {
            "x": -18000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 14,
        "title": "Diabetes Risk Calculation",
        "x": 5,
        "y": 10,
        "description":"<h5>Risk assessment tool for those not identified with prediabetes or diabetes:<h5><img src='https://i.imgur.com/qZ5PnaG.png'>&nbsp;The ADA risk calculator should be used to calculate the risk of developing diabetes.</h5><h5><img src='https://i.imgur.com/DGgDmcG.png'>&nbsp;A score of ≥5 indicates an increased risk of T2DM.</h5><img src='https://i.imgur.com/QqL2tsU.png' width='100%'><p class='carousel-caption' style='top:55%;width:80%;left:10%'>Confirmation by a doctor of a diagnosis of T2DM or prediabetes is recommended.<br/><a href='https://www.diabetes.org/risk-test' target='_blank'>Risk Test</a></p></h5>",
        "colour": "#ee2b2f",
        "label": {
            "x": -13000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    },
    {
        "id": 15,
        "title": "Other Diagnoses",
        "x": 15,
        "y": 14,
        "description":"<h5>Some other conditions can also be diagnosed during diabetes screening:<br/><h5><img src='https://i.imgur.com/4aZHO2A.png'>&nbsp;Dyslipidemia</h5><h5><img src='https://i.imgur.com/328fhf9.png'>&nbsp;Hypertension</h5><h5><img src='https://i.imgur.com/w1nPNB0.png'>&nbsp;Overweight or obesity</h5><h5><img src='https://i.imgur.com/6qoF93t.png'>&nbsp;Cessation of tobacco use</h5><h5><img src='https://i.imgur.com/CuxQSZs.png'>&nbsp;Depression</h5>Refer to the <a href='https://www.moph.gov.qa/english/OurServices/eservices/Pages/Clinical-Guidelines.aspx' target='_blank'>MOPH National Clinical Guidelines</a> for detailed information on management.</h5>",
        "colour": "#f27aaa",
        "label": {
            "x": -8000,
            "y": 8000
        },
        "type": "M7342 10267 l-2652 -2652 2655 -2655 2655 -2655 2655 2655 2655 2655 -2652 2652 c-1459 1459 -2655 2653 -2658 2653 -3 0 -1199 -1194 -2658 -2653z"
    },
    {
        "id": 16,
        "title": "Lifestyle Improvement Advice",
        "x": 10,
        "y": 6,
        "description":"<h5>All people should be encouraged to follow heart healthy lifestyle habits including:<ul><li>Adhering to a heart-healthy diet.</li><li>Maintenance of a healthy body weight.</li><li>Regular physical activity habits:<ul><li>Aim for reducing sedentariness and increasing walking, progressing to moderate-intensity physical activity (such as brisk walking), gradually increased to at least 150 min/week.</li><li>Consider using the Physical Activity Readiness Questionnaire for Safe Exercise (PARQ) to assess an individual’s safety to commence exercise.</li><li>Those individuals considered at high risk of ASCVD should be referred to a cardiologist for review prior to commencing exercise.</li></ul></li><li>Cessation of tobacco products.</li></ul></h5>",
        "colour": "#f92828",
        "label": {
            "x": -16000,
            "y": 8000
        },
        "type": "M4650 7780 l0 -5230 5235 0 5235 0 0 5230 0 5230 -5235 0 -5235 0 0-5230z"
    },
    {
        "id": 17,
        "title": "Frequency of Repeat Screening",
        "x": 10,
        "y": 4,
        "description":"<h3><b>Frequency of Screening</b></h3><h5>Screening should occur at the following intervals:</h5><br/><h5><b>In all adults, aged over 40 years</b></h5><ul><li>Screen every 3 years.</li><li>Consider further annual screening, if risk factors are identified.</li></ul><br/><h3><b>In adults aged less than 40 years, with two or more of risk factors</b></h3><h5><ul><li>Initial screening should be performed at the time the person is identified, and thereafter the individual should undergo treatment of any identified disease or risk factors.</li><li>Those undergoing treatment for hypertension and/or dyslipidemia – screen for DM and prediabetes, annually.</li><li>In all other cases, repeat screening at least every 3 years.</li></ul><br/></h5><h3><b>Frequency of atherosclerosis risk assessment</b></h3><h5>In adults who are free from ASCVD:<ul><li>Estimate 10-year ASCVD risk every 4-6 years in adults 40-75 years of age.</li><li>Risk assessment should be repeated every 4–6 years in adults who are found to be at low 10-year risk (<5%).</li><li>Consider assessment of 30-year or lifetime ASCVD risk on the basis of traditional risk factors in adults 20–59 years of age who are free from ASCVD and are not at high or intermediate short-term risk (10-year <5%).</li></h5>",
        "colour": "#f92828",
        "label": {
            "x": -13000,
            "y": 8000
        },
        "type": "M9749 12469 c-1183 -61 -2298 -569 -3129 -1425 -741 -764 -1180 -1700 -1307 -2789 -13 -115 -17 -230 -17 -490 0 -260 4 -375 17 -490 127 -1089 566 -2025 1307 -2789 520 -536 1145 -934 1845 -1176 985 -340 2085 -340 3070 0 700 242 1325 640 1845 1176 741 764 1180 1700 1307 2789 13 115 17 230 17 490 0 452 -30 716 -129 1123 -279 1147 -985 2148 -1980 2807 -712 473 -1497 729 -2370 775 -208 11 -258 11 -476 -1z"
    }
]